Evaluating Tumor Heterogeneity with a High Throughput Pipeline
An automated bioprinting and imaging platform allows researchers to examine heterogeneous responses to anticancer drugs within a tumor organoid population.
Evaluating Tumor Heterogeneity with a High Throughput Pipeline
Evaluating Tumor Heterogeneity with a High Throughput Pipeline
An automated bioprinting and imaging platform allows researchers to examine heterogeneous responses to anticancer drugs within a tumor organoid population.
An automated bioprinting and imaging platform allows researchers to examine heterogeneous responses to anticancer drugs within a tumor organoid population.
Islands of rigid cells within a matrix of soft ones allow tumors to be both solid and fluid, granting them toughness without losing the ability to break apart.
At Brigham and Women’s Hospital, the cancer biologist is combining research into the tumor microenvironment with the principles of neuroscience to tease apart how cancers grow—and how to stop them.
Alejandra Manjarrez, PhD | Mar 25, 2022 | 5 min read
A new study reports that human colon cancer cells at imminent risk of death can instead develop characteristics needed to colonize new parts of the body.
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
By scrutinizing gene expression profiles instead of individual oncogenes, Todd Golub launched a powerful platform for diagnosing, classifying, and treating cancer.